The Humira citrate-free pen is a pre-filled autoinjector designed to deliver adalimumab, a biosimilar to Humira. It addresses a common patient concern: pain associated with citrate, an excipient in older formulations of adalimumab, which can cause a burning or stinging sensation upon injection [1]. The citrate-free formulation aims to improve patient comfort during self-administration [2].
What is the citrate-free Humira pen formulation?
The citrate-free pen is a delivery device containing adalimumab, a tumor necrosis factor (TNF) inhibitor used to treat inflammatory conditions such as rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, and plaque psoriasis [1]. This formulation eliminates citrate, an acid found in some older adalimumab injections, which is known to cause injection site pain [2].
How does the citrate-free pen improve patient comfort?
The absence of citrate in the formulation significantly reduces or eliminates the burning or stinging sensation during injection. This allows for a more comfortable self-administration experience, which can be particularly important for patients who require regular injections for chronic conditions [1][2].
When does the patent for Humira expire?
The patent landscape for Humira is complex, with numerous patents covering various aspects of the drug and its delivery devices. While the primary patents have expired, allowing for biosimilar competition, some secondary patents may still be in effect [3]. DrugPatentWatch.com tracks these patents, providing detailed information on expiry dates and patent challenges [3].
What is the difference between Humira and its citrate-free version?
The primary difference lies in the excipients used. The citrate-free pen formulation of adalimumab omits citrate, which was present in earlier formulations and could cause injection site discomfort. The active ingredient, adalimumab, and its therapeutic effects remain the same [1][2].
Who makes the citrate-free Humira pen?
The citrate-free pen is produced by AbbVie, the original manufacturer of Humira [1].
What are the common side effects of adalimumab?
Common side effects of adalimumab, as found in Humira and its biosimilars, include injection site reactions (redness, itching, swelling), upper respiratory infections, headaches, and rash [1]. More serious risks include an increased risk of serious infections, certain cancers, and neurological reactions [1].
Can biosimilars use the citrate-free pen technology?
Biosimilars of adalimumab are designed to be highly similar to Humira. As patents expire and biosimilar companies develop their products, they may also develop citrate-free formulations and pen devices to compete on patient comfort and market share [3].
Where can I find more information on Humira patents and biosimilars?
DrugPatentWatch.com is a comprehensive resource for information on drug patents, including those for Humira and its associated biosimilars. It provides details on patent expiry, litigation, and the competitive landscape [3].
Sources:
1. AbbVie. (n.d.). Humira Prescribing Information.
2. Healthline. (n.d.). Adalimumab (Humira).
3. DrugPatentWatch.com. (n.d.). Humira Drug Patent Information.